SoFi Technologies (NASDAQ: SOFI), Robinhood Markets (NASDAQ: HOOD), and TransMedics Group (NASDAQ: TMDX) have each underperformed the broader market this year, creating potential entry points for long-term investors.
Buying quality stocks during temporary pullbacks, rather than chasing them at peak valuations, has long been one of the most reliable strategies for generating above-average returns.
SoFi shares have fallen 34% this year, battered by a short-seller report and investor disappointment with the company’s forward guidance following its first-quarter earnings release.
The company categorically denied the allegations made in the short-seller report, and its underlying financial results tell a notably different story from the negative sentiment surrounding the stock.
SoFi’s total revenue jumped 43% year over year to $1.1 billion, marking a record quarterly net revenue figure for the fintech company, while adjusted earnings per share doubled to $0.12.
The company’s membership base also hit a record 14.7 million users, representing 35% growth from the same period a year earlier, underscoring the platform’s continued momentum.
Near-term headwinds remain, particularly if macroeconomic conditions deteriorate, but the strength of SoFi’s underlying business makes a compelling case for investors comfortable with volatility.
Robinhood delivered 15% revenue growth year over year to $1.07 billion in the first quarter, though its cryptocurrency business proved to be a significant drag on overall performance.
Crypto trading revenue at Robinhood came in at $134 million, a steep 47% decline compared to the prior-year period, which weighed heavily on top-line results and investor sentiment.
The company is actively working to reduce its dependence on volatile crypto revenues, with Gold premium subscription sales growing steadily and prediction-market ventures adding another diversification layer.
Robinhood has evolved into a fully fledged financial institution serving investors, active traders, and retirement savers, positioning it as a serious long-term contender in the financial services industry.
TransMedics Group has carved out a dominant position in the organ transplant market through its proprietary Organ Care System, a portable device that keeps donor organs viable before transplantation by mimicking human body physiology.
The OCS technology has helped reduce organ waste and post-transplant complications, giving TransMedics a defensible and medically significant niche within the broader healthcare sector.
TransMedics posted first-quarter revenue growth of 21% year over year, reaching $173.9 million, though rising expenses pushed its operating margin down sharply to 7.6% from 19.1% in the prior-year period.
Adjusted earnings per share came in at $0.30, a significant drop from the $0.74 reported in the same quarter a year ago, which disappointed Wall Street and sent the stock lower.
The expense increases are tied to deliberate strategic investments, including international expansion and the build-out of a proprietary logistics network to support organ transport operations.
TransMedics is also channeling funds into research and development to seek regulatory approval for the OCS across additional organ types, including kidneys, beyond its current clearances for lungs, hearts, and livers.
All three companies are navigating short-term pressures that have obscured their longer-term growth trajectories, and patient investors willing to look past near-term noise may find these dips rewarding over the next decade.
